ATLANTA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR). The lawsuit alleges that Defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company’s business, operations, and compliance policies, including allegations that: (i) Defendants had overstated the Dovitinib new drug application’s (“NDA”) continued regulatory prospects; (ii) Al ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ___________ Commission File Number: 001-41160 ALLARITY THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | --- | --- | |-- ...

NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Allarity Therapeutics, Inc. (NASDAQ: ALLR) resulting from allegations that Allarity Therapeutics, Inc. may have issued materially misleading business information to the investing public. So what: If you purchased Allarity securities you may be entitled to compensation without payment of any out of pocket fees or costs thro ...

NEW YORK, Aug. 2, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Allarity Therapeutics, Inc. (NASDAQ: ALLR) ("Allarity" or "the Company").The investigation focuses on whether the Company issued false and/or misleading statements and/or did not disclose information pertinent to investors.PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATIONOn July ...

NEW YORK, July 31, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Allarity Therapeutics, Inc. (NASDAQ: ALLR) ("Allarity" or "the Company"). The investigation focuses on whether the Company issued false and/or misleading statements and/or did not disclose information pertinent to investors. PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION On  ...

NEW YORK, July 28, 2024 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Allarity Therapeutics, Inc. (NASDAQ: ALLR) resulting from allegations that Allarity Therapeutics, Inc. may have issued materially misleading business information to the investing public.So what: If you purchased Allarity securities you may be entitled to compensation without payment of any out of pocket fees or costs through a c ...

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Allarity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] ...

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. (“Allarity” or “the Company”) (NASDAQ: ALLR). Investors who purchased Allarity securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ALLR. Investigation Details On July 22, 2024, Allarity filed a current report on Form 8-K with the SEC and disclo ...

Boston (July 26, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, announced that its Board of Directors has decided to postpone the Annual Meeting of Stockholders, which was originally scheduled for 10:00 AM Eastern Time today, July 26, 2024. On July 25, 2024, the Board, exercising its authority under the Company's bylaws, opted to delay the meeting to a future date, which w ...

Boston (July 26, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, announced that its Board of Directors has decided to postpone the Annual Meeting of Stockholders, which was originally scheduled for 10:00 AM Eastern Time today, July 26, 2024. On July 25, 2024, the Board, exercising its authority under the Company’s bylaws, opted to delay the meeting to a future date, which ...